Sector Gamma AS Grows Position in TG Therapeutics, Inc. $TGTX

Key Points

• Sector Gamma AS has increased its stake in TG Therapeutics by 49.1%, owning approximately 0.05% of the company after purchasing an additional 27,000 shares, bringing its total to 82,000 shares valued at about $2.95 million.
• Several analysts have updated their ratings on TG Therapeutics, with Goldman Sachs upgrading to a "hold" and B. Riley rating it a "buy" with a price target of $55.00.
• Director Sagar Lonial sold 20,852 shares at an average price of $32.24, resulting in an 18.15% reduction in his shareholdings.

Sector Gamma AS boosted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 49.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 82,000 shares of the biopharmaceutical company's stock after purchasing an additional 27,000 shares during the period. Sector Gamma AS owned approximately 0.05% of TG Therapeutics worth $2,951,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Ameritas Advisory Services LLC purchased a new position in shares of TG Therapeutics in the 2nd quarter worth $25,000. Golden State Wealth Management LLC increased its stake in TG Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 433 shares during the last quarter. SVB Wealth LLC purchased a new position in shares of TG Therapeutics in the 1st quarter worth about $37,000. Private Wealth Asset Management LLC acquired a new position in shares of TG Therapeutics in the 2nd quarter valued at about $37,000. Finally, Brooklyn Investment Group grew its holdings in shares of TG Therapeutics by 2,159.2% during the 1st quarter. Brooklyn Investment Group now owns 1,604 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 1,533 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on TGTX shares. The Goldman Sachs Group upgraded shares of TG Therapeutics to a "hold" rating and set a $37.00 price target on the stock in a report on Thursday, July 10th. B. Riley boosted their price target on TG Therapeutics from $53.00 to $55.00 and gave the stock a "buy" rating in a research report on Wednesday, September 17th. HC Wainwright started coverage on shares of TG Therapeutics in a research report on Monday, October 6th. They issued a "buy" rating and a $60.00 price objective for the company. Finally, Weiss Ratings reiterated a "hold (c-)" rating on shares of TG Therapeutics in a research note on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $49.00.

Insiders Place Their Bets

In other news, Director Sagar Lonial sold 20,852 shares of the business's stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the completion of the sale, the director owned 94,061 shares of the company's stock, valued at approximately $3,032,526.64. The trade was a 18.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 10.64% of the stock is currently owned by corporate insiders.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX opened at $33.49 on Friday. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89. TG Therapeutics, Inc. has a fifty-two week low of $22.61 and a fifty-two week high of $46.48. The business has a 50 day moving average price of $32.77 and a two-hundred day moving average price of $34.97. The firm has a market cap of $5.31 billion, a PE ratio of 90.51 and a beta of 1.97.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.15). TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The business had revenue of $141.15 million for the quarter, compared to analysts' expectations of $147.76 million. During the same quarter last year, the company posted $0.04 earnings per share. The business's quarterly revenue was up 92.1% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS. Sell-side analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.